PE20252048A1 - Anticuerpos monoclonales anti-slc34a2 y sus usos - Google Patents

Anticuerpos monoclonales anti-slc34a2 y sus usos

Info

Publication number
PE20252048A1
PE20252048A1 PE2024003122A PE2024003122A PE20252048A1 PE 20252048 A1 PE20252048 A1 PE 20252048A1 PE 2024003122 A PE2024003122 A PE 2024003122A PE 2024003122 A PE2024003122 A PE 2024003122A PE 20252048 A1 PE20252048 A1 PE 20252048A1
Authority
PE
Peru
Prior art keywords
antibody
fragment
slc34a2
monoclonal antibodies
relates
Prior art date
Application number
PE2024003122A
Other languages
English (en)
Spanish (es)
Inventor
Runsheng Li
Wentao Huang
Yifan Li
Original Assignee
Lanova Medicines Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanova Medicines Dev Co Ltd filed Critical Lanova Medicines Dev Co Ltd
Publication of PE20252048A1 publication Critical patent/PE20252048A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2024003122A 2022-06-22 2023-06-21 Anticuerpos monoclonales anti-slc34a2 y sus usos PE20252048A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022100315 2022-06-22
PCT/CN2023/101761 WO2023246879A1 (en) 2022-06-22 2023-06-21 Anti-slc34a2 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PE20252048A1 true PE20252048A1 (es) 2025-08-21

Family

ID=89379184

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024003122A PE20252048A1 (es) 2022-06-22 2023-06-21 Anticuerpos monoclonales anti-slc34a2 y sus usos

Country Status (14)

Country Link
US (2) US12215150B2 (cg-RX-API-DMAC10.html)
EP (1) EP4543926A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025520692A (cg-RX-API-DMAC10.html)
KR (1) KR20250051643A (cg-RX-API-DMAC10.html)
CN (1) CN119948054A (cg-RX-API-DMAC10.html)
AU (1) AU2023289743A1 (cg-RX-API-DMAC10.html)
CA (1) CA3260354A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024004012A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024017740A2 (cg-RX-API-DMAC10.html)
IL (1) IL317849A (cg-RX-API-DMAC10.html)
MX (1) MX2025000053A (cg-RX-API-DMAC10.html)
PE (1) PE20252048A1 (cg-RX-API-DMAC10.html)
TW (1) TW202409076A (cg-RX-API-DMAC10.html)
WO (1) WO2023246879A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024408814A1 (en) * 2023-12-21 2026-07-09 LaNova Medicines Limited Conjugates of anti-slc34a2 antibody and uses thereof
CN120988123B (zh) * 2025-10-21 2026-03-17 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
US20250154248A1 (en) 2025-05-15
CA3260354A1 (en) 2023-12-28
EP4543926A1 (en) 2025-04-30
CN119948054A (zh) 2025-05-06
JP2025520692A (ja) 2025-07-03
IL317849A (en) 2025-02-01
US12215150B2 (en) 2025-02-04
CO2024017740A2 (es) 2025-05-19
KR20250051643A (ko) 2025-04-17
MX2025000053A (es) 2025-04-02
US20240301052A1 (en) 2024-09-12
TW202409076A (zh) 2024-03-01
WO2023246879A1 (en) 2023-12-28
CL2024004012A1 (es) 2025-05-02
AU2023289743A1 (en) 2025-01-09